SEGMENTS

We currently manage our operations in two reportable segments, pharmaceuticals and diagnostics. The pharmaceuticals segment consists of two operating segments, our (i) pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products, and vaccines, and (ii) the pharmaceutical operations we acquired in Chile, Mexico, Israel, Spain, Brazil, and Uruguay. The diagnostics segment consists of two operating segments, our (i) pathology operations we acquired through the acquisition of OPKO Lab and (ii) point-of-care and molecular diagnostics operations. There are no significant inter-segment sales. We evaluate the performance of each segment based on operating profit or loss. There is no inter-segment allocation of interest expense and income taxes.

Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:



	For the three months ended March 31,
(In thousands)	2015			2014
Product revenues:
Pharmaceuticals	$	15,486		$	19,828
Diagnostics	—			—
Corporate	—			—
	$	15,486		$	19,828
Revenue from services:
Pharmaceuticals	$	—		$	—
Diagnostics	2,009			1,910
Corporate	60			60
	$	2,069		$	1,970
Revenue from transfer of intellectual property:
Pharmaceuticals	$	12,529		$	285
Diagnostics	—			191
Corporate	—			—
	$	12,529		$	476
Operating (loss) income:
Pharmaceuticals	$	(37,924	)	$	(16,573	)
Diagnostics	(8,477		)	(7,078		)
Corporate	(9,979		)	(6,137		)
Less: Operating loss attributable to noncontrolling interests	(534		)	(489		)
	$	(56,914	)	$	(30,277	)
Depreciation and amortization:
Pharmaceuticals	$	1,756		$	1,849
Diagnostics	1,747			1,691
Corporate	22			24
	$	3,525		$	3,564
Net loss from investment in investees:
Pharmaceuticals	$	(1,761	)	$	(2,056	)
Diagnostics	—			—
Corporate	—			—
	$	(1,761	)	$	(2,056	)
Revenues:
United States	$	2,493		$	2,446
Ireland	12,104			—
Chile	6,452			7,285
Spain	3,937			6,150
Israel	4,213			4,546
Mexico	885			1,831
Other	—			16
	$	30,084		$	22,274



(In thousands)	March 31, 2015		December 31, 2014
Assets:
Pharmaceuticals	$	1,098,031	$	1,064,498
Diagnostics	105,751		108,072
Corporate	308,467		95,094
	$	1,512,249	$	1,267,664
Goodwill:
Pharmaceuticals	$	172,254	$	173,327
Diagnostics	50,965		50,965
Corporate	—		—
	$	223,219	$	224,292

During the three months ended March 31, 2015, revenue recognized under the Pfizer Transaction represented 42% of our total revenue. Refer to Note 12. During the three months ended March 31, 2014, no customer represented more than 10% of our total revenue. As of March 31, 2015 and December 31, 2014, no customer represented more than 10% of our accounts receivable balance.